Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids
Wei Qiu,Ming Zhou,Mausumi Mazumdar,Arezki Azzi,Dalila Ghanmi,Van Luu‐The,Fernand Labrie,Sheng‐Xiang Lin
DOI: https://doi.org/10.1074/jbc.m606784200
2007-01-01
Abstract:Human type 5 17β-hydroxysteroid dehydrogenase plays a crucial role in local androgen formation in prostate tissue. Several chemicals were synthesized and tested for their ability to inhibit this enzyme, and a series of estradiol derivatives bearing a lactone on the D-ring were found to inhibit its activity efficiently. The crystal structure of the type 5 enzyme in complex with NADP and such a novel inhibitor, EM1404, was determined to a resolution of 1.30Aå. Significantly more hydrogen bonding and hydrophobic interactions were defined between EM1404 and the enzyme than in the substrate ternary complex. The lactone ring of EM1404 accounts for important interactions with the enzyme, whereas the amide group at the opposite end of the inhibitor contributes to the stability of three protein loops involved in the construction of the substrate binding site. EM1404 has a strong competitive inhibition, with a Ki of 6.9 ± 1.4 nm, demonstrating 40 times higher affinity than that of the best inhibitor previously reported. This is observed despite the fact that the inhibitor occupies only part of the binding cavity. Attempts to soak the inhibitor into crystals of the binary complex with NADP were unsuccessful, yielding a structure with a polyethylene glycol fragment occupying the substrate binding site. The relative crystal packing is discussed. Combined studies of small molecule inhibitor synthesis, x-ray crystallography, enzyme inhibition, and molecular modeling make it possible to analyze the plasticity of the substrate binding site of the enzyme, which is essential for developing more potent and specific inhibitors for hormone-dependent cancer therapy. Human type 5 17β-hydroxysteroid dehydrogenase plays a crucial role in local androgen formation in prostate tissue. Several chemicals were synthesized and tested for their ability to inhibit this enzyme, and a series of estradiol derivatives bearing a lactone on the D-ring were found to inhibit its activity efficiently. The crystal structure of the type 5 enzyme in complex with NADP and such a novel inhibitor, EM1404, was determined to a resolution of 1.30Aå. Significantly more hydrogen bonding and hydrophobic interactions were defined between EM1404 and the enzyme than in the substrate ternary complex. The lactone ring of EM1404 accounts for important interactions with the enzyme, whereas the amide group at the opposite end of the inhibitor contributes to the stability of three protein loops involved in the construction of the substrate binding site. EM1404 has a strong competitive inhibition, with a Ki of 6.9 ± 1.4 nm, demonstrating 40 times higher affinity than that of the best inhibitor previously reported. This is observed despite the fact that the inhibitor occupies only part of the binding cavity. Attempts to soak the inhibitor into crystals of the binary complex with NADP were unsuccessful, yielding a structure with a polyethylene glycol fragment occupying the substrate binding site. The relative crystal packing is discussed. Combined studies of small molecule inhibitor synthesis, x-ray crystallography, enzyme inhibition, and molecular modeling make it possible to analyze the plasticity of the substrate binding site of the enzyme, which is essential for developing more potent and specific inhibitors for hormone-dependent cancer therapy. According to the American Cancer Society, prostate cancer is the most common malignant tumor, excluding skin cancers, in American men. It is estimated that ∼232,090 new cases of prostate cancer will be diagnosed in the US during 2005 with 30,350 deaths (www.cancer.org). The growth and function of the prostate is dependent on androgens, which play important roles in the pathogenesis of prostate cancer (1Lopez-Otin C. Diamandis E.P. Endocr. Rev. 1998; 19: 365-396Crossref PubMed Scopus (182) Google Scholar). Androgen withdrawal triggers the programmed cell apoptosis in both normal prostate glandular epithelia and androgen-dependent prostate cancer cells. Androgen-independent prostate cancer cells do not initiate the programmed cell death pathway upon androgen withdrawal; however, they do retain the cellular machinery necessary to activate the apoptotic cascade when sufficiently damaged by exogenous agents (2Denmeade S.R. Lin X.S. Isaacs J.T. Prostate. 1996; 28: 251-265Crossref PubMed Scopus (389) Google Scholar). In prostate cancer, the balance between cell proliferation and programmed cell death is lost, thus more cell proliferation results in net cell growth. An important finding in prostate cancer research is that ∼50% of dihydrotestosterone, the most potent natural androgen, remains in the prostatic tissue of patients who have undergone surgical or chemical castration (3Labrie F. Dupont A. Belanger A. Giguere M. Lacoursiere Y. Emond J. Monfette G. Bergeron V. J. Steroid Biochem. 1985; 23: 833-841Crossref PubMed Scopus (140) Google Scholar). In fact, prostatic tissue is able to efficiently transform the inactive adrenal steroid precursor dehydroepiandrosterone, into the active androgen dihydrotestosterone, in a new androgen biosynthetic pathway in which human type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5) 4The abbreviations used are: 17β-HSD5, 17β-hydroxysteroid dehydrogenase type 5; AKR, aldoketo reductase; PEG, polyethylene glycol; EM1404, 3-carboxamido-1,3,5-(10)-estratrien-17(R)-spiro-2′-(5′,5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N; E2, estradiol. 4The abbreviations used are: 17β-HSD5, 17β-hydroxysteroid dehydrogenase type 5; AKR, aldoketo reductase; PEG, polyethylene glycol; EM1404, 3-carboxamido-1,3,5-(10)-estratrien-17(R)-spiro-2′-(5′,5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N; E2, estradiol. is involved (4Pelletier G. Luu-The V. Tetu B. Labrie F. J. Histochem. Cytochem. 1999; 47: 731-738Crossref PubMed Scopus (92) Google Scholar, 5Pelletier G. Li S. Luu-The V. Tremblay Y. Belanger A. Labrie F. J. Endocrinol. 2001; 171: 373-383Crossref PubMed Scopus (81) Google Scholar, 6El-Alfy M. Luu-The V. Huang X.F. Berger L. Labrie F. Pelletier G. Endocrinology. 1999; 140: 1481-1491Crossref PubMed Google Scholar, 7Labrie F. Cusan L. Gomez J.L. Candas B. Belanger A. Luu-The V. Labrie C. Simard J. Med. Sci. (Paris). 2003; 19: 910-919Crossref PubMed Scopus (4) Google Scholar). In practice, hormonal therapy with combined androgen blockade could lead to even longer term control of localized prostate cancer (8Labrie F. Dupont A. Belanger A. Cusan L. Lacourciere Y. Monfette G. Laberge J.G. Emond J.P. Fazekas A.T. Raynaud J.P. Husson J.M. Clin. Invest. Med. 1982; 5: 267-275PubMed Google Scholar, 9Labrie F. Candas B. Gomez J.L. Cusan L. Urology. 2002; 60: 115-119Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). 17β-HSD5 has also been known as type 2 3α-HSD (10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar), prostaglandin 11-ketoreductase (prostaglandin F synthetase) (11Matsuura K. Shiraishi H. Hara A. Sato K. Deyashiki Y. Ninomiya M. Sakai S. J. Biochem. (Tokyo). 1998; 124: 940-946Crossref PubMed Scopus (158) Google Scholar), and dihydrodiol dehydrogenase (12Burczynski M.E. Harvey R.G. Penning T.M. Biochemistry. 1998; 37: 6781-6790Crossref PubMed Scopus (132) Google Scholar). It is a member of the aldoketo reductase (AKR) family with a designated name of AKR1C3 (13Jez J.M. Bennett M.J. Schlegel B.P. Lewis M. Penning T.M. Biochem. J. 1997; 326: 625-636Crossref PubMed Scopus (534) Google Scholar, 14Jez J.M. Flynn T.G. Penning T.M. Biochem. Pharmacol. 1997; 54: 639-647Crossref PubMed Scopus (335) Google Scholar) and was first cloned from human prostate and placenta cDNA libraries (10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar, 15Dufort I. Rheault P. Huang X.F. Soucy P. Luu-The V. Endocrinology. 1999; 140: 568-574Crossref PubMed Scopus (240) Google Scholar). It has been proven that this enzyme has a relatively high 17β-HSD activity that transforms Δ4-androstene-3,17-dione (4-dione, a weak androgen) to testosterone (a potent androgen). This enzyme has been immunocytochemically localized in human prostate tissues, and it has been proposed to contribute to local androgen formation in prostate (4Pelletier G. Luu-The V. Tetu B. Labrie F. J. Histochem. Cytochem. 1999; 47: 731-738Crossref PubMed Scopus (92) Google Scholar, 5Pelletier G. Li S. Luu-The V. Tremblay Y. Belanger A. Labrie F. J. Endocrinol. 2001; 171: 373-383Crossref PubMed Scopus (81) Google Scholar, 6El-Alfy M. Luu-The V. Huang X.F. Berger L. Labrie F. Pelletier G. Endocrinology. 1999; 140: 1481-1491Crossref PubMed Google Scholar, 16Lin H.K. Steckelbroeck S. Fung K.M. Jones A.N. Penning T.M. Steroids. 2004; 69: 795-801Crossref PubMed Scopus (110) Google Scholar, 17Nakamura Y. Suzuki T. Nakabayashi M. Endoh M. Sakamoto K. Mikami Y. Moriya T. Ito A. Takahashi S. Yamada S. Arai Y. Sasano H. Endocr. Relat. Cancer. 2005; 12: 101-107Crossref PubMed Scopus (81) Google Scholar). The enzyme conformational change during 4-dione to testosterone conversion was demonstrated by the first crystal structures of 17β-HSD5 in complex with either 4-dione or testosterone (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar). The 11-ketoreductase activity of this enzyme has also been studied in association with prostaglandin D2 and some inhibitors (20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar). Blockade of this enzyme could lead to the activation of a nuclear receptor (peroxisome proliferator-activated receptor-γ), which induces cell differentiation, and results in apoptosis in many cell types and cancers (22Wick M. Hurteau G. Dessev C. Chan D. Geraci M.W. Winn R.A. Heasley L.E. Nemenoff R.A. Mol. Pharmacol. 2002; 62: 1207-1214Crossref PubMed Scopus (140) Google Scholar, 23Desmond J.C. Mountford J.C. Drayson M.T. Walker E.A. Hewison M. Ride J.P. Luong Q.T. Hayden R.E. Vanin E.F. Bunce C.M. Cancer Res. 2003; 63: 505-512PubMed Google Scholar). The gene that encodes 17β-HSD5 was assigned to human chromosome bands 10p15 and p14 (24Rheault P. Dufort I. Soucy P. Luu-The V. Cytogenet. Cell Genet. 1999; 84: 241-242Crossref PubMed Google Scholar). 17β-HSD5 mRNA was also reported to be expressed in prostate cancer tissues (25Koh E. Noda T. Kanaya J. Namiki M. Prostate. 2002; 53: 154-159Crossref PubMed Scopus (82) Google Scholar). In a recent study, 17β-HSD5 immunoreactivity was detected in 77% of carcinoma cells from prostate cancer tissues and was positively associated with the clinical stage of the disease (17Nakamura Y. Suzuki T. Nakabayashi M. Endoh M. Sakamoto K. Mikami Y. Moriya T. Ito A. Takahashi S. Yamada S. Arai Y. Sasano H. Endocr. Relat. Cancer. 2005; 12: 101-107Crossref PubMed Scopus (81) Google Scholar). This provides some evidence that 17β-HSD5 may possibly be involved in the increase of the local concentration of testosterone. Both reductive and oxidative 17β-HSD activities are present in prostate tissue (26Bartsch W. Greeve J. Voigt K.D. J. Steroid. Biochem. 1987; 28: 35-42Crossref PubMed Scopus (17) Google Scholar, 27Martel C. Rheaume E. Takahashi M. Trudel C. Couet J. Luu-The V. Simard J. Labrie F. J. Steroid Biochem. Mol. Biol. 1992; 41: 597-603Crossref PubMed Scopus (234) Google Scholar), assumed by different members of the 17β-HSD family members. Using the androgen-sensitive LNCaP prostate cancer cell line as a cell model to study the progression of prostate cancer, it has been reported that substantial changes in androgen and estrogen metabolism occur in the cells during this process. A remarkable decrease in the oxidative 17β-hydroxysteroid dehydrogenase activity was seen, whereas the reductive activity (including 17β-HSD5 and 17β-HSD7) seemed to increase (28Soronen P. Laiti M. Torn S. Harkonen P. Patrikainen L. Li Y. Pulkka A. Kurkela R. Herrala A. Kaija H. Isomaa V. Vihko P. J. Steroid Biochem. Mol. Biol. 2004; 92: 281-286Crossref PubMed Scopus (70) Google Scholar). It has also been reported that 17β-HSD5 mRNA expression was significantly higher in breast tumor specimens than in normal tissue after analysis of 794 breast carcinoma specimens by tissue microarray and normal histologic sections (29Oduwole O.O. Li Y. Isomaa V.V. Mantyniemi A. Pulkka A.E. Soini Y. Vihko P.T. Cancer Res. 2004; 64: 7604-7609Crossref PubMed Scopus (107) Google Scholar). This suggests that the ability of 17β-HSD5 to regulate estrogen metabolism may play an important role in breast cancer development. It is also interesting to point out that 17β-HSD5 plays an important site-specific role in androgen generation in adipose tissue in women with simple obesity (30Quinkler M. Sinha B. Tomlinson J.W. Bujalska I.J. Stewart P.M. Arlt W. J. Endocrinol. 2004; 183: 331-342Crossref PubMed Scopus (132) Google Scholar). Due to the importance of this enzyme, not only in prostate cancer research but also in other hormone-related diseases, the design of an inhibitor targeting this key enzyme has been widely pursued (31Krazeisen A. Breitling R. Moller G. Adamski J. Adv. Exp. Med. Biol. 2002; 505: 151-161Crossref PubMed Scopus (26) Google Scholar, 32Penning T.M. Burczynski M.E. Jez J.M. Lin H.K. Ma H. Moore M. Ratnam K. Palackal N. Mol. Cell. Endocrinol. 2001; 171: 137-149Crossref PubMed Scopus (87) Google Scholar, 33Bauman D.R. Rudnick S.I. Szewczuk L.M. Jin Y. Gopishetty S. Penning T.M. Mol. Pharmacol. 2005; 67: 60-68Crossref PubMed Scopus (109) Google Scholar, 34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar, 35Krazeisen A. Breitling R. Moller G. Adamski J. Mol. Cell. Endocrinol. 2001; 171: 151-162Crossref PubMed Scopus (142) Google Scholar). The crystal structure of 17β-HSD5 is a necessary prerequisite for structure-based drug design. The enzyme was first crystallized in our laboratory (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar), and structures in complex with testosterone or 4-dione were determined (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar). To date, eight crystal structures of AKR1C3 in different complexes have been published (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar, 20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar). The plasticity of its substrate binding site in accommodating different ligands and its importance in hormone-related diseases led us to investigate further the structure-function relationships of this enzyme. The functional plasticity of the AKR1C3 as well as 1C1 and 1C2 enzymes has been discussed by Penning and colleagues previously (37Penning T.M. Burczynski M.E. Jez J.M. Hung C.F. Lin H.K. Ma H. Moore M. Palackal N. Ratnam K. Biochem. J. 2000; 351: 67-77Crossref PubMed Scopus (540) Google Scholar). Being aware that any subtle difference at the active site could be important for structure-based inhibitor design, we have studied the active site of the enzyme in detail by comparing the different docking properties of various inhibitors and ligands in the crystallographic structures. In this study, we report the crystal structure of 17β-HSD5 in complex with a potent inhibitor EM1404 and another structure with a segment of polyethylene glycol (PEG) made from 6 ethylene glycol units (C12H25O6) bound in the active site. Enzyme inhibition by EM1404 was also studied, and the comparison with other inhibitors has been discussed. Furthermore, we intended to explore the interactions between this potent inhibitor and its target enzyme, 17β-HSD5, and to provide suggestions for the improvement of inhibitor design based on the crystal structure. Purification and Crystallization—Human 17β-HSD5-glutathione S-transferase was overexpressed in Escherichia coli and purified by glutathione S-transferase affinity column and a Blue Sepharose column as described previously (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar). After purification the protein was kept in potassium phosphate stock buffer of pH 7.5, in the presence of 10 mm K2HPO4, 1 mm EDTA, 1 mm dithiothreitol, 0.05% decylmaltoside, 1.2 mm NADP. The glutathione S-transferase tag was cleaved by overnight incubation at 4 °C with Thrombin protease. EM1404 was co-crystallized with 17β-HSD5 and NADP. Due to the low solubility of EM1404, it was first dissolved in 100% Me2SO to a concentration of 25 mm and then diluted in 100% ethanol to a final concentration of 2.5 mm as a stock solution. It was added to protein-NADP complex solution (∼2 μl of this stock solution into 2 ml of total mixture volume) to reach a final concentration of 2.5 μm. The mixture was then concentrated 10-20 times before being diluted to ∼2 ml by adding the same stock buffer mentioned above. Additional EM1404 was added once more, which could be then dissolved (see “Discussion”). The same concentration-dilution procedure was repeated to saturate the enzyme substrate binding site by the inhibitor. The protein was finally concentrated to ∼10-15 mg/ml. The co-crystallization condition of the EM1404 ternary complex has been refined from the former conditions crystallizing testosterone and 4-dione complexes (36Zhou M. Qiu W. Chang H.J. Gangloff A. Lin S.X. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002; 58: 1048-1050Crossref PubMed Scopus (7) Google Scholar). The reservoir solution contained 100 mm sodium citrate, pH 5.6, 0.24 m ammonium acetate, and 30% PEG 4000. Human 17β-HSD5·NADP crystals were obtained at room temperature using the hanging-drop vapor diffusion method by mixing equal volumes of protein and a reservoir solution of 30% PEG 4000, 0.1 m sodium citrate, pH 5.6, 0.24 m ammonium acetate. During our first attempts, 17β-HSD5·NADP (final enzyme concentration 330 μm in the crystallization drop after equilibrium) binary complex crystals were soaked with repeated additions of EM1404 (final inhibitor concentration 560 μm), and similar crystal space groups were obtained (Table 1)TABLE 1Data collection and refinement statistics of crystal structures of 17β-HSD5·EM1404·NADP and 17β-HSD5·PEG·NADP17β-HSD5·EM1404·NADP17β-HSD5·PEG·NADPData processing statisticsPDB code1ZQ52FGBSpace groupP212121P212121Unit cell (Aå)a = 55.35, b = 62.78, c = 95.97a = 55.52, b = 61.65, c = 95.12Resolution range (Aå)29.8-1.3047.6-1.35Highest shell range (Aå)1.37-1.301.38-1.35Total reflections251,431 (23,897)aStatistics of the highest resolution shell are shown in parentheses.220,439 (7,354)aStatistics of the highest resolution shell are shown in parentheses.Unique reflections79,292 (10,401)68,648 (3,474)Mosaicity (°)0.320.38Multiplicity3.2 (2.3)3.2 (2.1)Completeness (%)95.9 (87.0)94.4 (65.2)Rmerge (%)bRmerge = ∑hkl∑j|Ij(hkl) - [I(hkl) ]|∑hkl∑j|Ij(hkl)|, where Ij(hkl) and [I(hkl) ] are the intensity of measurement j and the mean intensity for the reflection with indices hkl, respectively.5.4 (42.4)6.5 (47.5)Mean(I)/σ(I)11.9 (2.1)9.6 (2.0)Refinement statisticsReflections75,29368,644Resolution range (Aå)29.8-1.3047.6-1.35Highest shell range (Aå)1.33-1.301.38-1.35Rcryst (%)cRcryst and Rfree = ∑hkl||Fcalc(hkl)| - |Fobs(hkl)||/∑hkl|Fobs|, where the crystallographic and free R-factors are calculated, including and excluding refined reflections, respectively. The Rfree reflections set constituted 5% of the total number of reflections.18.1 (30.0)17.2 (25.9)Rfree (%)19.7 (35.4)19.0 (29.7)Average B-value (A2)Protein11.5115.5Ligand8.4412.5Water24.7726.9Root mean square deviation from idealityBonds (Aå)0.0080.007Angle (°)1.3321.255Ramachandran plot (% residue in CORE)91.893.2Model content321 residues, 315 H2O, 1 EM1404, 1NADP, and 1 acetate323 residues, 402 H2O, 1 PEG, 1 NADP, and 1 acetatea Statistics of the highest resolution shell are shown in parentheses.b Rmerge = ∑hkl∑j|Ij(hkl) - [I(hkl) ]|∑hkl∑j|Ij(hkl)|, where Ij(hkl) and [I(hkl) ] are the intensity of measurement j and the mean intensity for the reflection with indices hkl, respectively.c Rcryst and Rfree = ∑hkl||Fcalc(hkl)| - |Fobs(hkl)||/∑hkl|Fobs|, where the crystallographic and free R-factors are calculated, including and excluding refined reflections, respectively. The Rfree reflections set constituted 5% of the total number of reflections. Open table in a new tab Data Collection and Processing—Both datasets of 17β-HSD5·EM1404·NADP and 17β-HSD5·PEG fragment·NADP were collected at the X-8C beamline in National Synchrotron Light Source, Brookhaven National Laboratory. Datasets were processed using the Mosflm (39Leslie A.G.W. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography. 1992; (No. 26)Google Scholar) and HKL packages (40Otwinowski Z. Minor W. Methods Enzymol. 1997; 276: 307-326Crossref PubMed Scopus (38526) Google Scholar). The processing statistics data are given in Table 1. Structure Solution and Refinement—The initial phases of 17β-HSD5·EM1404·NADP was obtained from a molecular replacement method using the EPMR program (41Kissinger C.R. Gehlhaar D.K. Fogel D.B. Acta Crystallogr. Sect. D Biol. Crystallogr. 1999; 55: 484-491Crossref PubMed Scopus (690) Google Scholar). A data set from 15 to 4 Aå resolution was used in molecular replacement. The coordinates of the protein structure from the 17β-HSD5-testosterone-NADP complex in the P21 space group were used as the starting model. A correlation coefficient factor of 0.568 and an R-factor of 41.9% were obtained before any refinement. The initial phases of 17β-HSD5·PEG·NADP were obtained using a similar method. Starting from the molecular replacement model, the programs Resolve (42Terwilliger T.C. Acta Crystallogr. Sect. D Biol. Crystallogr. 2003; 59: 38-44Crossref PubMed Scopus (593) Google Scholar) and Refmac from the CCP4 package (43Number Collaborative Computational Project Acta Crystallogr. Sect. D Biol. Crystallogr. 1994; 50: 760-763Crossref PubMed Scopus (19748) Google Scholar) were used to improve phases using a statistical density modification method. Rigid body refinement was done with data from 29 to 3.0 Aå resolution. Automatic model rebuilding was carried out based on a prime-and-switch composite omit map to reduce any model bias due to refinement. Multiple refinement cycles were carried out using the program Refmac, and model building was done by the Coot program (44Emsley P. Cowtan K. Acta Crystallogr. Sect. D Biol. Crystallogr. 2004; 60: 2126-2132Crossref PubMed Scopus (23224) Google Scholar) based on sigma-A weighted 2Fo - Fc electron density maps. The last refinement steps were done with data from 29 to 1.30 Aå resolution. The inhibitor position was very clear in the substrate binding site from the electron density maps. An acetate molecule was also identified near the substrate and cofactor binding sites and was induced during the co-crystallization (see above). The program Coot was also used to add water into the model. In the final model, 356 water molecules were included with good hydrogen bonding geometry. Both structures have been deposited in the PDB, the ID for 17β-HSD5·EM1404·NADP structure is 1ZQ5, while that for 17β-HSD5·PEG fragment·NADP is 2FGB. Inhibition Study—A radioactive assay was used for the enzyme kinetics in the presence of EM1404 at different concentrations for its Ki determination. Purified 17β-HSD5, freshly frozen at -80 °C in small aliquots until use, has demonstrated very good reproduction of steady-state kinetics. The reactions were carried out in the presence of an excess of NADP (200 μm) at pH 7.5 and 37 ± 0.5 °C. The Km for testosterone oxidation in the absence of EM-1404, and four apparent Km values in the presence of 1, 3, 10, and 25 nm EM-1404, were determined. Reactions were initiated by the addition of enzyme sample to a final concentration of 200 nm in the reaction mixture, aliquots of the reaction mixture were taken, and the reaction was stopped at different time intervals by extracting the steroids with 2.5× vol. of diethyl ether. The steroids were extracted, separated by TLC migration in 80% toluene and 20% acetone for a 10-cm distance, and analyzed by phosphorimaging. Initial velocities were measured with <5% substrate consumption. The experiments were repeated with different concentrations of testosterone ranging from 0.8 to 10 μm. To obtain an optimal signal, larger reaction mixture volumes were used for low substrate concentrations (i.e. 3-ml reaction mixtures for 0.8 μm testosterone, 2 ml for 1.8 μm, 1 ml for 4 μm, and 0.5 ml for 10 μm). All experiments were performed in duplicate. IC50 values indicated the inhibitor concentration leading to 50% inhibition of the enzyme activity under the experimental conditions described in Ref. 34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar. The values were calculate using Equation 1, 1/v=Km/Vmax⋅(1+[f]JK1)⋅1/[S]+1/VmaxEq. 1 where v is the initial velocity in the presence of different substrate concentrations, Vmax is the maximum velocity, and [S] and [I] are the substrate and inhibitor concentrations (48Segel L.A. J. Theor. Biol. 1976; 57: 23-42Crossref PubMed Scopus (26) Google Scholar). The respective apparent Km values in the presence of different inhibitor concentrations were then plotted versus these concentrations as shown by the inset of Fig. 5, the slope of which defines Km/Ki (48Segel L.A. J. Theor. Biol. 1976; 57: 23-42Crossref PubMed Scopus (26) Google Scholar), based on the linear regression of Equation 2. Kmapp=Km(1+[f]/Ki)Eq. 2 Molecular Dynamics Simulation—The simulations were based on the crystal structure for the complex EM1404 and the docked structure for the complex with the newly proposed inhibitor (Fig. 8C). MD simulations were performed with the program GROMACS (www.gromacs.org) version 3.3.1 (details are in the supplemental material). The GROMACS forcefield parameters were employed for the simulations. Overall Structure—The inhibitor EM1404 (3-carboxamido-1,3,5-(10Lin H.K. Jez J.M. Schlegel B.P. Peehl D.M. Pachter J.A. Penning T.M. Mol. Endocrinol. 1997; 11: 1971-1984Crossref PubMed Google Scholar)-estratrien-17(R)-spiro-2′-(5′, 5′-dimethyl-6′-oxo)tetrahydropyran, C25H30O3N, Fig. 1A) was first obtained from a chemical screen (34Labrie F. Belanger A. Gauthier S. Luu-The V. Merand Y. Poirier D. Provencher L. Singh S.M. Inhibitors of Type 5 and Type 3 17beta-Hydroxysteroid Dehydrogenase and Methods for Their Use. 1999; (Canada PCT, WO99/46279)Google Scholar) where it was shown to have an IC50 (see definition in method) of 3.2 ± 1.5 nm, the best among the inhibitors designed for 17β-HSD5. The strong affinity of EM1404 is further proven in the inhibition mechanism study below. The ternary complex structure of 17β-HSD5·EM1404·NADP was determined by molecular replacement using a searching model obtained from the 17β-HSD5·testosterone·NADP complex (18Qiu W. X-ray Crystallographic Studies on Human Estrogenic Type 1 and Androgenic Type 5 17beta-Hydroxysteroid Dehydrogenases, Ph.D. dissertation, Laval University, Quebec City, Quebec, Canada. 2002; Google Scholar). Its overall structure is similar to the other crystal forms (19Qiu W. Zhou M. Labrie F. Lin S-X. Mol. Endocrinol. 2004; 18: 1798-1807Crossref PubMed Scopus (65) Google Scholar, 20Komoto J. Yamada T. Watanabe K. Takusagawa F. Biochemistry. 2004; 43: 2188-2198Crossref PubMed Scopus (84) Google Scholar, 21Lovering A.L. Ride J.P. Bunce C.M. Desmond J.C. Cummings S.M. White S.A. Cancer Res. 2004; 64: 1802-1810Crossref PubMed Scopus (103) Google Scholar), with an (α/β)8 triose-phosphate isomerase barrel motif, a typical structure of the aldoketo reductase family. Four large loops, namely loop-A (24Rheault P. Dufort I. Soucy P. Luu-The V. Cytogenet. Cell Genet. 1999; 84: 241-242Crossref PubMed Google Scholar, 25Koh E. Noda T. Kanaya J. Namiki M. Prostate. 2002; 53: 154-159Crossref PubMed Scopus (82) Google Scholar, 26Bartsch W. Greeve J. Voigt K.D. J. Steroid. Biochem. 1987; 28: 35-42Crossref PubMed Scopus (17) Google Scholar, 27Martel C. Rheaume E. Takahashi M. Trudel C. Couet J. Luu-The V. Simard J. Labrie F. J. Steroid Biochem. Mol. Biol. 1992; 41: 597-603Crossref PubMed Scopus (234) Google Scholar, 28Soronen P. Laiti M. Torn S. Harkonen P. Patrikainen L. Li Y. Pulkka A. Kurkela R. Herrala A. Kaija H. Isomaa V. Vihko P. J. Steroid Biochem. Mol. Biol. 2004; 92: 281-286Crossref PubMed Scopus (70) Google Scholar, 29Oduwole O.O. Li Y. Isomaa V.V. Manty
What problem does this paper attempt to address?
-
Crystal Structures Of The Multispecific 17 Beta-Hydroxysteroid Dehydrogenase Type 5: Critical Androgen Regulation In Human Peripheral Tissues
Wei Qiu,Ming Zhou,Fernand Labrie,Sheng-Xiang Lin
DOI: https://doi.org/10.1210/me.2004-0032
2004-01-01
Molecular Endocrinology
Abstract:Human type 5 17 beta-hydroxysteroid dehydrogenase ( 17beta-HSD5; AKR1C3) plays a major role in the metabolism of androgens in peripheral tissues. In prostate basal cells, this enzyme is involved in the transformation of dehydroepiandrosterone into dihydrotestosterone, the most potent androgen. It is thus a potential target for prostate cancer therapy because it is understood that the testosterone formation by this enzyme is an important factor, particularly in patients who have undergone surgical or medical castration. Here we report the first structure of a human type 5 17beta-HSD in two ternary complexes, in which we found that the androstenedione molecule has a different binding position from that of testosterone. The two testosterone-binding orientations in the substrate-binding site demonstrate the structural basis of the alternative binding and multispecificity of the enzyme. Phe306 and Trp227 are the key residues involved in ligand recognition as well as product release. A safety belt in the cofactor-binding site enhances nicotinamide adenine dinucleotide phosphate binding and accounts for its high affinity as demonstrated by kinetic studies. These structures have provided a dynamic view of the enzyme reaction converting androstenedione to testosterone as well as valuable information for the development of potent enzyme inhibitors.
-
Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues
F Labrie,J Simard,V Luu-The,A Bélanger,G Pelletier
DOI: https://doi.org/10.1016/0960-0760(92)90308-6
Abstract:The membrane-bound enzyme 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase (3β-HSD) catalyses an essential step in the transformation of all 5-pregnen-3β-ol and 5-androsten-3β-ol steroids into the corresponding 3-keto-4-ene-steroids, namely progesterone as well as all the precursors of androgens, estrogens, glucocorticoids and mineralocorticoids. We have recently characterized two types of human 3β-HSD cDNA clones and the corresponding genes which encode type I and II 3β-HSD isoenzymes of 372 and 371 amino acids, respectively, and share 93.5% homology. The human 3β-HSD genes containing 4 exons were assigned by in situ hybridization to the p11-p13 region of the short arm of chromosome 1. Human type I 3β-HSD is the almost exclusive mRNA species present in the placenta and skin while the human type II is the predominant mRNA species in the adrenals, ovaries and testes. The type I protein possesses higher 3β-HSD activity than type II. We elucidated the structures of three types of rat 3β-HSD cDNAs as well that of one type of 3β-HSD from bovine and macaque ovary λgt11 cDNA libraries, which all encode a 372 amino acid protein. The rat type I and II 3β-HSD proteins expressed in the adrenals, gonads and adipose tissue share 93.8% homology. Transient expression of human type I and II as well as rat type I and II 3β-HSD cDNAs in HeLa human cervical carcinoma cells reveals that 3β-ol dehydrogenase and 5-ene-4-ene isomerase activities reside within a single protein. These expressed 3β-HSD proteins convert 3β-hydroxy-5-ene-steroids into 3-keto-4-ene derivatives and catalyze the interconversion of 3β-hydroxy and 3-keto-5α-androstane steroids. By site-directed mutagenesis, we demonstrated that the lower activity of expressed rat type II compared to rat type I 3β-HSD is due to a change of four residues probably involved in a membrane-spanning domain. When homogenates from cells transfected with a plasmid vector containing rat type I 3β-HSD is incubated in the presence of dihydrotestosterone (DHT) using NAD⁺ as co-factor, 5α-androstanedione was formed (A-dione), indicating an intrinsic androgenic 17β-hydroxysteroid dehydrogenase (17β-HSD) activity of this 3β-HSD. We cloned a third type of rat cDNA encoding a predicted type III 3β-HSD specifically expressed in the rat liver, which shares 80% similarity with the two other isoenzymes. Transient expression in human HeLa cells reveals that the type III isoenzyme does not display oxidative activity for the classical substrates of 3β-HSD. However, in common with the type I enzyme, it converts A-dione and DHT to the corresponding 3β-hydroxysteroids, thus showing an exclusive 3-ketosteroid reductase activity. When NADPH is used as co-factor, the affinity for DHT of the type III enzyme becomes 10-fold higher than that of the type I. Rat type III mRNA was below the detection limit in intact female liver. Following hypophysectomy, its concentration increased to 55% of the values measured in intact or hypophysectomized male rats, an increase which can be blocked by administration of ovine prolactin (oPRL). Treatment with oPRL for 10 days starting 15 days after hypophysectomy markedly decreased ovarian 3β-HSD mRNA accumulation accompanied by a similar decrease in 3β-HSD activity and protein levels. Treatment with the gonadotropin hCG reversed the potent inhibitory effect of oPRL on these parameters and stimulated 3β-HSD mRNA levels in ovarian interstitial cells. These data indicate that the presence of multiple 3β-HSD isoenzymes offers the possibility of tissue-specific expression and regulation of this enzymatic activity that plays an essential role in the biosynthesis of all hormonal steroids in classical as well as peripheral intracrine steroidogenic tissues.
-
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.
Xue-Ying He,Ying-Zi Yang,Donna M Peehl,Alexander Lauderdale,Horst Schulz,Song-Yu Yang
DOI: https://doi.org/10.1016/j.jsbmb.2003.07.007
IF: 5.011
2003-01-01
The Journal of Steroid Biochemistry and Molecular Biology
Abstract:In vitro enzyme assays have demonstrated that human type 10 17β-hydroxysteroid dehydrogenase (17β-HSD10) catalyzes the oxidation of 5α-androstane-3α,17β-diol (adiol), an almost inactive androgen, to dihydrotestosterone (DHT) rather than androsterone or androstanedione. To further investigate the role of this steroid-metabolizing enzyme in intact cells, we produced stable transfectants expressing 17β-HSD10 or its catalytically inactive Y168F mutant in human embryonic kidney (HEK) 293 cells. It was found that DHT levels in HEK 293 cells expressing 17β-HSD10, but not its catalytically inactive mutant, will dramatically increase if adiol is added to culture media. Moreover, certain malignant prostatic epithelial cells have more 17β-HSD10 than normal controls, and can generate DHT, the most potent androgen, from adiol. This event might promote prostate cancer growth. Analysis of the 17β-HSD10 sequence shows that this enzyme does not have any ER retention signal or transmembrane segments and has not originated by divergence from a retinol dehydrogenase. The data suggest that the unique mitochondrial location of this HSD [Eur. J. Biochem. 268 (2001) 4899] does not prevent it from oxidizing the 3α-hydroxyl group of a C19 sterol in living cells. The experimental results lead to the conclusion that mitochondrial 17β-HSD10 plays a significant part in a non-classical androgen synthesis pathway along with microsomal retinol dehydrogenases.
-
Steroidal antiandrogens and 5alpha-reductase inhibitors
E Bratoeff,E Ramírez,E Murillo,G Flores,M Cabeza
Abstract:The purpose of this work is to synthesize a pregnane derivative with a high antiandrogenic effect or a high inhibitory activity for the enzyme 5 alpha-reductase type 2. Benign prostatic hyperplasia and prostate cancer are androgen dependent diseases which afflict a large percentage of the male population. Dihydrotestosterone 3, a 5 alpha-reductase metabolite of testosterone 2 has been implicated as a causative factor in the progression of these diseases, largely through the clinical evaluation of males who are genetically deficient of steroid 5 alpha-reductase enzyme. As a result of this study, the inhibition of this enzyme has become a pharmacological strategy for the design and synthesis of new drugs. The advent of finasteride 22 "figure 5" a 5 alpha-reductase inhibitor, has greatly alleviated the symptoms associated with benign prostatic hyperplasia. On the other hand, the discovery of cyproterone acetate 4 "figure 2" alone or in combination with the antiandrogens flutamide 14 "figure 3" or bicalutamide 21 has greatly reduced the misery of prostate cancer. Prostate cancer kills about 40,000 men in the USA and approximately 400,000 prostatectomies are performed each year. In our laboratory we have recently synthesized ten new progesterone derivatives 17 alpha-acyloyloxy-6-halo (chloro, bromo) 16 beta-methyl-4, 6-pregnadiene-3, 20-diones (54a-54e and 55a-55e), "figure 10". These steroids were evaluated as antiandrogens and exhibited a much higher activity than the commercially available cyproterone acetate 4. The same compounds were also evaluated as 5 alpha-reductase inhibitors and showed a slightly higher inhibitory activity than that of finasteride 22, the drug of choice today for the treatment of benign prostatic hyperplasia In another study we synthesized several new 4-halo (bromo and chloro) 17 alpha-benzoyloxy and also 4-halo-17 alpha-acetoxy progesterone derivatives (58-63) "figure 13". These compounds were prepared from the commercially available 17 alpha-acetoxy progesterone 56. The pharmacological evaluation of these steroids "figure 14" indicated that the 17 alpha-benzoyloxy derivatives (4-chloro and bromo) 62 and 63 were very potent antiandrogens. On the other hand, the 4-halo (bromo and chloro) 17 alpha-acetoxy (58, 59) and the 17 alpha-benzoyloxy-4-chloro analog 63 showed a very high inhibitory activity for the enzyme 5 alpha-reductase type 2 "figure 15".
-
Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5Α-Reductases
Hwei-Ming Peng,Juan Valentin-Goyco,Sang-Choul Im,Bing Han,Jiayan Liu,Jie Qiao,Richard J. Auchus
DOI: https://doi.org/10.1210/endocr/bqaa117
IF: 5.051
2020-01-01
Endocrinology
Abstract:The potent androgen 5 alpha-dihydrotestosterone irreversibly derives from testosterone via the activity of steroid 5 alpha-reductases (Sails). The major 5 alpha R isoforms in most species, 5 alpha R1 and 5 alpha R2, have not been purified to homogeneity. We report here the heterologous expression of polyhistidine-tagged, codon-optimized human 5 alpha R1 and 5 alpha R2 cDNAs in Escherichia coli. A combination of the nonionic detergents Triton X-100 and Nonidet P-40 enabled solubilization of these extremely hydrophobic integral membrane proteins and facilitated purification with affinity and cation-exchange chromatography methods. For functional reconstitution, we incorporated the purified isoenzymes into Triton X-100-saturated dioleoylphosphatidylcholine liposomes and removed excess detergent with polystyrene beads. Kinetic studies indicated that the 2 isozymes differ in biochemical properties, with 5 alpha R2 having a lower apparent K-m for testosterone, androstenedione, progesterone, and 17-hydroxyprogesterone than 5 alpha R1;however, 5 alpha R1 had a greater capacity for steroid conversion, as reflected by a higher V-max than 5 alpha R2. Both enzymes preferred progesterone as substrate over other steroids, and the catalytic efficiency of purified reconstituted 5 alpha R2 exhibited a sharp pH optimum at pH 5. Intriguingly, we found that the prostate-cancer drug-metabolite 3-keto-Delta(4)-abiraterone is metabolized by 5 alpha R1 but not 5 alpha R2, which may serve as a structural basis for isoform selectivity and inhibitor design. The functional characterization results with the purified reconstituted isoenzymes paralleled trends obtained with HEK-293 cell lines stably expressing native 5 alpha R1 and 5 alpha R2. Access to purified human 5 alpha R1 and 5 alpha R2 will advance studies of these important enzymes and might help to clarify their contributions to steroid anabolism and catabolism.
-
A Concerted, Rational Design of Type 1 17β‐hydroxysteroid Dehydrogenase Inhibitors: Estradiol‐adenosine Hybrids with High Affinity
W Qiu,RL Campbell,A Gangloff,P Dupuis,RP Boivin,MR Tremblay,D Poirier,SX Lin
DOI: https://doi.org/10.1096/fj.02-0026fje
2002-01-01
The FASEB Journal
Abstract:Human estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 1) catalyzes the final step in the synthesis of active estrogens that stimulate the proliferation of breast cancer cells. Based on the initial premise to make use of the binding energies of both the substrate and cofactor sites, and molecular modeling starting from the enzyme structure, several estradiol-adenosine hybrids were designed and synthesized. Among these hybrids, EM-1745 with a linker of 8-CH2 groups is proved to be the best competitive inhibitor with a Ki of 3.0 +/- 0.8 nM. The crystal structure of the EM-1745 enzyme complex at 1.6 A provides evidence at atomic resolution of strong interactions between both the steroid and cofactor moieties and the enzyme molecule, as illustrated by a deltaA-weighted 2Fo-Fc electron density map contoured at 3.0 delta. The substrate entry loop is further stabilized in this complex compared with previous complexes of the enzyme. These results confirm our initial strategy of combining studies of structural biology and enzyme mechanism in the inhibitor design, which may be applied to other steroidogenic enzymes involved in human diseases.
-
Human 3-Alpha Hydroxysteroid Dehydrogenase Type 3 (3Α-Hsd3): the V54L Mutation Restricting the Steroid Alternative Binding and Enhancing the 20Α-Hsd Activity.
Bo Zhang,Dao-Wei Zhu,Xiao-Jian Hu,Ming Zhou,Peng Shang,Sheng-Xiang Lin
DOI: https://doi.org/10.1016/j.jsbmb.2014.01.003
IF: 5.011
2014-01-01
The Journal of Steroid Biochemistry and Molecular Biology
Abstract:Human 3-alpha hydroxysteroid dehydrogenase type 3 (3α-HSD3) has an essential role in the inactivation of 5α-dihydrotestosterone (DHT). Notably, human 3α-HSD3 shares 97.8% sequence identity with human 20-alpha hydroxysteroid dehydrogenase (20α-HSD) and there is only one amino acid difference (residue 54) that is located in their steroid binding pockets. However, 20α-HSD displays a distinctive ability in transforming progesterone to 20α-hydroxy-progesterone (20α-OHProg). In this study, to understand the role of residue 54 in the steroid binding and discrimination, the V54L mutation in human 3α-HSD3 has been created. We have solved two crystal structures of the 3α-HSD3·NADP(+)·Progesterone complex and the 3α-HSD3 V54L·NADP(+)·progesterone complex. Interestingly, progesterone adopts two different binding modes to form complexes within the wild type enzyme, with one binding mode similar to the orientation of a bile acid (ursodeoxycholate) in the reported ternary complex of human 3α-HSD3·NADP(+)·ursodeoxycholate and the other binding mode resembling the orientation of 20α-OHProg in the ternary complex of human 20α-HSD·NADP(+)·20α-OHProg. However, the V54L mutation directly restricts the steroid binding modes to a unique one, which resembles the orientation of 20α-OHProg within human 20α-HSD. Furthermore, the kinetic study has been carried out. The results show that the V54L mutation significantly decreases the 3α-HSD activity for the reduction of DHT, while this mutation enhances the 20α-HSD activity to convert progesterone.
-
Secosteroid Mechanism-Based Inactivators and Site-Directed Mutagenesis As Probes for Steroid Hormone Recognition by 3.Alpha.-Hydroxysteroid Dehydrogenase
BP SCHLEGEL,JE PAWLOWSKI,YF HU,DM SCOLNICK,DF COVEY,TM PENNING
DOI: https://doi.org/10.1021/bi00200a017
IF: 3.321
1994-01-01
Biochemistry
Abstract:Rat liver 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD, EC 1.1.1.50) inactivates circulating androgens, progestins, and glucocorticoids. 3 alpha-HSD is a member of the aldo-keto reductase superfamily, and the X-ray structure of the apoenzyme shows the presence of an (alpha/beta)8 barrel [Hoog, S. S., Pawlowski, J. E., Alzari, P. M., Penning, T. M., & Lewis, M. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 2517-2521]. As yet, a three-dimensional structure of the ternary complex E.NADPH.steroid is unavailable. To identify regions of the enzyme involved in steroid hormone recognition, we have employed mechanism-based inactivators and site-directed mutagenesis. (3 RS)-1,10-Seco-5 alpha-estr-1-yne-3,17 beta-diol (1) and (17 RS)- 17-hydroxy-14,15-secoandrost-4-en-15-yn-3-one (3) are secosteroids which contain latent Michael acceptors (alpha,beta-unsaturated alcohols) at opposite ends of the steroid nucleus (at the C-3 and C-17 positions, respectively). It was found that compounds 1 and 3 inactivated 3 alpha-HSD only in the presence of NAD+. The requirement for cofactor implies that 1 and 3 are oxidized to the corresponding alpha,beta-unsaturated ketones for inactivation to occur. Chemically prepared 17 beta-hydroxy-1,10-seco-5 alpha-estr-1-yn-3-one (2) and 14,15-secoandrost-4-en-15-yne-3,17-dione (4), the presumed products of 1 and 3 oxidation, behaved as stoichiometric inactivators of 3 alpha-HSD. In the presence and absence of NAD+, 2 and 4 inactivated > 50% of the enzyme in 10 s or less.(ABSTRACT TRUNCATED AT 250 WORDS)
-
Type 10 17Beta-Hydroxysteroid Dehydrogenase Catalyzing the Oxidation of Steroid Modulators of Γ-Aminobutyric Acid Type A Receptors
XY He,J Wegiel,YZ Yang,R Pullarkat,H Schulz,SY Yang
DOI: https://doi.org/10.1016/j.mce.2004.08.011
IF: 4.369
2005-01-01
Molecular and Cellular Endocrinology
Abstract:The steroids allopregnanolone and allotetrahydrodeoxycorticosterone (3alpha,5alpha-THDOC) are positive allosteric modulators of GABA(A) receptors, generated by the reduction of 5alpha-dihydroprogesterone (5alpha-DHP) and 5alpha-DHDOC, respectively, under the catalysis of human type 3 3alpha-hydroxysteroid dehydrogenase (HSD). However, brain enzymes catalyzing the conversion of such tetrahydrosteroids back to the corresponding 5alpha-dihydrosteroids remain to be identified. Characterization of human type 10 17beta-HSD provides a new insight into its importance for the oxidation of steroid modulators of GABA(A) receptors. The apparent catalytic efficiency (k(cat)/K(m)) of this enzyme for the oxidation of allopregnanolone and 3alpha,5alpha-THDOC are 432 and 1381 min(-1) mM(-1), respectively. This enzyme has negligible 3-ketosteroid reductase activity for 5alpha-DHP and 5alpha-DHDOC even in an acidic environment. Immunoreactivity against 17beta-HSD10 was found in a number of neuronal populations. Taken together, evidence suggests that 17beta-HSD10 is the brain enzyme capable of catalyzing the oxidation of steroid modulators of GABA(A) receptors.
-
Purification, Crystallization and Preliminary X-Ray Diffraction Results of Human 17 Beta-Hydroxysteroid Dehydrogenase Type 5
M Zhou,W Qiu,HJ Chang,A Gangloff,SX Lin
DOI: https://doi.org/10.1107/s0907444902005255
2002-01-01
Abstract:17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) catalyze the last step in the biosynthesis of all androgens and estrogens, thus playing a pivotal role in sex-hormone metabolism. Human 17beta-HSD type 5 (17beta-HSD5) catalyzes hydride transfer at the 17beta-hydroxy position, but possesses high sequence homology to 3alpha-hydroxysteroid dehydrogenases (3alpha-HSD). Two crystal forms of 17beta-HSD5 in an enzyme-testosterone-NADP ternary complex have been obtained under different crystallization conditions. A form I crystal obtained at pH 8.5 diffracted to 1.32 Angstrom. It belonged to space group P2(1), with unit-cell parameters a = 47.41, b = 77.16, c = 48.67 Angstrom, beta = 116.32degrees. Form II crystals obtained at pH 6.5 diffracted to 2.0 Angstrom and belonged to space group P6(3), with unit-cell parameters a = b = 110.58, c = 56.89 Angstrom.
-
Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
S-X Lin,R Shi,W Qiu,A Azzi,D-W Zhu,H Al Dabbagh,M Zhou
DOI: https://doi.org/10.1016/j.mce.2005.11.035
IF: 4.369
2006-01-01
Molecular and Cellular Endocrinology
Abstract:17β-Hydroxysteroid dehydrogenases/ketosteroid reductases (17β-HSDs/KSRs) catalyze the last step of sex steroid synthesis or the first step of their degradation, and are thus critical for many physiological processes. The multispecificity demonstrated by 17β-HSDs is important for steroid metabolism in gonadal and peripheral tissues, and is a consequence of the architecture of their binding and catalytic sites. Structurally, most of the family members are short chain dehydrogenase-reductases (SDRs) except the type 5 enzyme, which is an aldo-keto reductase (AKR).
-
Design, Synthesis and Biological Evaluation of Novel Androst-3,5-diene-3-carboxylic Acid Derivatives As Inhibitors of 5Α-Reductase Type 1 and 2
Kejing Lao,Jie Sun,Chong Wang,Weiting Lyu,Boshen Zhou,Ruheng Zhao,Qian Xu,Qidong You,Hua Xiang
DOI: https://doi.org/10.1016/j.steroids.2017.05.011
IF: 2.76
2017-01-01
Steroids
Abstract:5α-Reductase is a key enzyme responsible for dihydrotestosterone biosynthesis and has been recognized as an important target for discovering new drugs against benign prostatic hyperplasia (BPH). In this study, a series of novel steroidal androst-3,5-diene-3-carboxylic acids have been designed and synthesized. Biological evaluations were performed on their 5α-reductase inhibitory activities by both in vitro enzyme inhibition assay and in vivo by prostate weighing method. Results showed that most of them displayed excellent 5α-reductase inhibitory potency. Detailed evaluation indicated that most of the compounds displayed slightly higher inhibition potency towards type 2 isozyme. Among all the compounds, 16a was found to be the most potential inhibitor with the IC50 of 0.25μM and 0.13μM against type 1 and 2 isozymes respectively. In vivo 5a-reductase inhibitory evaluation of 16a also showed a more significant reduction effect (p<0.001) in rat prostate weight than epristeride. Furthermore, the results of in silico ADME study indicated that compound 16a exhibited good pharmacokinetic properties. Thus, 16a could serve as promising lead candidates for further study.
-
Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors
Jean-Yves Sancéau,René Maltais,Ming Zhou,Sheng-Xiang Lin,Donald Poirier
DOI: https://doi.org/10.1016/j.jsbmb.2024.106544
Abstract:Sex steroid hormones such as estrogen estradiol (E2) and androgen dihydrotestosterone (DHT) are involved in the development of hormone-dependent cancers. Blockade of 17β-hydroxysteroid dehydrogenase type 7 (17β-HSD7), a member of the short chain dehydrogenase/reductase superfamily, is thought to decrease E2 levels while increasing those of DHT. Therefore, its unique double action makes this enzyme as an interesting drug target for treatment of breast cancer. The chemical synthesis, molecular characterization, and preliminary biological evaluation as 17β-HSD7 inhibitors of novel carbamate derivatives 3 and 4 are described. Like previous 17β-HSD7 inhibitors 1 and 2, compounds 3 and 4 bear a hydrophobic nonyl side chain at the C-17β position of a 4-aza-5α-androstane nucleus, but compound 3 has an oxygen atom replacing the CH2 in the steroid A-ring C-2 position, while compound 4 has a C17-spiranic E-ring containing a carbamate function. They both inhibited the in vitro transformation of estrone (E1) into E2 by 17β-HSD7, but the introduction of a (17 R)-spirocarbamate is preferable to replacing C-2 methylene with an oxygen atom since compound 4 (IC50 = 63 nM) is an inhibitor 14 times more powerful than compound 3 (IC50 = 900 nM). Furthermore, when compared to the reference inhibitor 1 (IC50 = 111 nM), the use of a C17-spiranic E-ring made it possible to introduce differently the hydrophobic nonyl side chain, without reducing the inhibitory activity.
-
Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone and androgen receptors-mediated transactivation
Takashi Yazawa,Yugo Watanabe,Yuko Yokohama,Yoshitaka Imamichi,Kazuya Hasegawa,Ke-Ichi Nakajima,Takeshi Kitano,Takanori Ida,Takahiro Sato,Mohammad Sayful Islam,Akihiro Umezawa,Satoru Takahashi,Yasuhito Kato,Sharmin Jahan,Jun-Ichi Kawabe
DOI: https://doi.org/10.3389/fendo.2024.1480722
2024-10-02
Abstract:3β-Hydroxysteroid dehydrogenases (3β-HSDs) catalyze the oxidative conversion of delta (5)-ene-3-beta-hydroxy steroids and ketosteroids. Human 3β-HSD type 2 (HSD3B2) is predominantly expressed in gonadal and adrenal steroidogenic cells for producing all classes of active steroid hormones. Mutations in HSD3B2 gene cause a rare form of congenital adrenal hyperplasia with varying degree of salt wasting and incomplete masculinization, resulting from reduced production of corticoids and androgens. Therefore, evaluation of the HSD3B2 enzymatic activity in both pathways for each steroid hormone production is important for accurately understanding and diagnosing this disorder. Using progesterone receptor (PR)- and androgen receptor (AR)-mediated transactivation, we adapted a method that easily evaluates enzymatic activity of HSD3B2 by quantifying the conversion from substrates [pregnenolone (P5) and dehydroepiandrosterone (DHEA)] to (progesterone and androstenedione). HEK293 cells were transduced to express human HSD3B2, and incubated medium containing P5 or DHEA. Depending on the incubation time with HSD3B2-expressing cells, the culture media progressively increased luciferase activities in CV-1 cells, transfected with the PR/AR expression vector and progesterone-/androgen-responsive reporter. Culture media from human and other mammalian HSD3B1-expressing cells also increased the luciferase activities. HEK293 cells expressing various missense mutations in the HSD3B2 gene revealed the potential of this system to evaluate the relationship between the enzymatic activities of mutant proteins and patient phenotype.
-
Evaluation of new pregnane derivatives as 5alpha-reductase inhibitor
M Cabeza,I Heuze,E Bratoeff,E Ramírez,R Martínez
DOI: https://doi.org/10.1248/cpb.49.525
Abstract:The objective of this study was to synthesize several new pregnane derivatives and evaluate them as antiandrogens. From the commercially available 16-dehydropregnenolone acetate (7), two new steroidal compounds were synthesized: 17alpha-hydroxy-17beta-methyl-16beta-phenyl-D-homoandrosta-1,4,6-triene-3,20-dione (18) and 17alpha-acetoxy-17beta-methyl-16beta-phenyl-D-homoandrosta-1,4,6-triene-3,20-dione (19). The 5alpha-reductase inhibitory effect of the new compounds 18 and 19 together with the previously synthesized intermediates 7, 8, 13, 16, and 17 was determined in three different models: gonadectomized hamster flank organs diameter size, incorporation of [1,2-(14)C]sodium acetate into lipids in flank organs and conversion of [3H]testosterone (T) to [3H]dihydrotestosterone (DHT) by Penicillium crustosum. The evaluation of these steroids was carried out with three different controls: one group was treated with vehicle, the second with T and the third group with T plus finasteride. The pharmacological results from this work demonstrated that T significantly increases the diameter of the pigmented spot on the flank organs (p<0.05) as well as the incorporation of labeled sodium acetate into lipids in gonadectomized hamster flank organs (from 0.125 to 0.255 nmol per gland). In this study we also observed that broth of Penicillium crustosum converted [3H]T to [3H]DHT in a manner comparable to that of the flank organs. All experiments indicated that finasteride as well as steroids 7, 8, 13, 16-19 reduced significantly the conversion of T to DHT in P. crustosum. These compounds also decrease the size of the pigmented spot in the flank organs as well as reducing the incorporation of radiolabeled sodium acetate into lipids; T and the control sample (treated with vehicle only) were used for comparison. Apparently the presence of the 4,6-diene-3,20-dione moiety and also the C-17 ester group produce a higher inhibitory effect on the parameters used. PPThe data from this study indicated also that the three models used for the pharmacological evaluation exhibited comparable results.
-
New 5alpha-reductase inhibitors: in vitro and in vivo effects
Víctor Pérez-Ornelas,Marisa Cabeza,Eugene Bratoeff,Ivonne Heuze,Mauricio Sánchez,Elena Ramírez,Elia Naranjo-Rodríguez
DOI: https://doi.org/10.1016/j.steroids.2004.11.008
IF: 2.76
Steroids
Abstract:The enzyme 5alpha-reductase is responsible for the conversion of testosterone (T) to its more potent androgen dihydrotestosterone (DHT). This steroid had been implicated in androgen-dependent diseases such as: benign prostatic hyperplasia, prostate cancer, acne and androgenic alopecia. The inhibition of 5alpha-reductase enzyme offers a potentially useful treatment for these diseases. In this study, we report the synthesis and pharmacological evaluation of several new 3-substituted pregna-4, 16-diene-6, 20-dione derivatives. These compounds were prepared from the commercially available 16-dehydropregnenolone acetate. The biological activity of the new steroidal derivatives was determined in vivo as well as in vitro experiments. In vivo experiments, the anti-androgenic effect of the steroids was demonstrated by the decrease of the weight of the prostate gland of gonadectomized hamster treated with T plus finasteride or the new steroids. The IC50 value of these steroids was determined by measuring the conversion of radio labeled T to DHT. The results of this study carried out with 5alpha-reductase enzyme from hamster and human prostate showed that four of the six steroidal derivatives (5, 7, 9, 10) exhibited much higher 5alpha-reductase inhibitory activity, as indicated by the IC50 values than the presently used Proscar 3 (finasteride). The comparison of the weight of the hamster's prostate gland indicated that compound 5 had a comparable weight decrease as finasteride. The overall data of this study showed very clearly those compounds 5, 7, 9, 10 are good inhibitors for the 5alpha-reductase enzyme.
-
Human 3 Alpha-Hydroxysteroid Dehydrogenase Type 3: Structural Clues Of 5 Alpha-Dht Reverse Binding And Enzyme Down-Regulation Decreasing Mcf7 Cell Growth
Bo Zhang,Xiao-Jian Hu,Xiao-Qiang Wang,Jean-Francois Theriault,Dao-Wei Zhu,Peng Shang,Fernand Labrie,Sheng-Xiang Lin
DOI: https://doi.org/10.1042/BCJ20160083
IF: 3.766
2016-01-01
Biochemical Journal
Abstract:Human 3 alpha-HSD3 (3 alpha-hydroxysteroid dehydrogenase type 3) plays an essential role in the inactivation of the most potent androgen 5 alpha-DHT (5 alpha-dihydrotestosterone). The present study attempts to obtain the important structure of 3 alpha-HSD3 in complex with 5 alpha-DHT and to investigate the role of 3 alpha-HSD3 in breast cancer cells. We report the crystal structure of human 3 alpha-HSD3 center dot NADP(+)center dot A-dione (5 alpha-androstane-3,17-dione)/ epi-ADT (epiandrosterone) complex, which was obtained by co-crystallization with 5 alpha-DHT in the presence of NADP(+). Although 5 alpha-DHT was introduced during the crystallization, oxidoreduction of 5 alpha-DHT occurred. The locations of A-dione and epi-ADT were identified in the steroid-binding sites of two 3 alpha-HSD3 molecules per crystal asymmetric unit. An overlay showed that A-dione and epi-ADT were oriented upside-down and flipped relative to each other, providing structural clues for 5 alpha-DHT reverse binding in the enzyme with the generation of different products. Moreover, we report the crystal structure of the 3 alpha-HSD3 center dot NADP(+)center dot 4-dione (4-androstene-3,17-dione) complex. When a specific siRNA (100 nM) was used to suppress 3 alpha-HSD3 expression without interfering with 3 alpha-HSD4, which shares a highly homologous active site, the 5 alpha-DHT concentration increased, whereas MCF7 cell growth was suppressed. The present study provides structural clues for 5 alpha-DHT reverse binding within 3 alpha-HSD3, and demonstrates for the first time that down-regulation of 3 alpha-HSD3 decreases MCF7 breast cancer cell growth.
-
Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride
Qingpin Xiao,Lei Wang,Shreyas Supekar,Tao Shen,Heng Liu,Fei Ye,Junzhou Huang,Hao Fan,Zhiyi Wei,Cheng Zhang
DOI: https://doi.org/10.1038/s41467-020-19249-z
IF: 16.6
2020-10-27
Nature Communications
Abstract:Abstract Human steroid 5α-reductase 2 (SRD5A2) is an integral membrane enzyme in steroid metabolism and catalyzes the reduction of testosterone to dihydrotestosterone. Mutations in the SRD5A2 gene have been linked to 5α-reductase deficiency and prostate cancer. Finasteride and dutasteride, as SRD5A2 inhibitors, are widely used antiandrogen drugs for benign prostate hyperplasia. The molecular mechanisms underlying enzyme catalysis and inhibition for SRD5A2 and other eukaryotic integral membrane steroid reductases remain elusive due to a lack of structural information. Here, we report a crystal structure of human SRD5A2 at 2.8 Å, revealing a unique 7-TM structural topology and an intermediate adduct of finasteride and NADPH as NADP-dihydrofinasteride in a largely enclosed binding cavity inside the transmembrane domain. Structural analysis together with computational and mutagenesis studies reveal the molecular mechanisms of the catalyzed reaction and of finasteride inhibition involving residues E57 and Y91. Molecular dynamics simulation results indicate high conformational dynamics of the cytosolic region that regulate NADPH/NADP + exchange. Mapping disease-causing mutations of SRD5A2 to our structure suggests molecular mechanisms for their pathological effects. Our results offer critical structural insights into the function of integral membrane steroid reductases and may facilitate drug development.
multidisciplinary sciences
-
Two Non-Reactive Ternary Complexes of Estrogenic 17Β-Hydroxysteroid Dehydrogenase: Crystallization and Preliminary Structural Analysis
W Qiu,DW Zhu,A Azzi,RL Campbell,H Qi,D Poirier,SX Lin
DOI: https://doi.org/10.1016/s0960-0760(99)00036-9
1999-01-01
Abstract:Human estrogenic 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD1, EC1.1.1.62) is an important enzyme that catalyses the last step of active estrogen formation. 17 beta-HSDI plays a key role in the proliferation of breast cancer cells. The three-dimensional structures of this enzyme and of the enzyme-estradiol complex have been solved (Zhu et al., 1993, J. Mol. Biol. 234:242; Ghosh et al., 1995, Structure 3:503; Azzi et al., 1996, Nature Struct. Biol. 3.665). The determination of the non-reactive ternary complex structure, which could mimic the transition state, constitutes a further critical step toward the rational design of inhibitors for this enzyme (Ghosh et al. 1995, Structure 3:503; Penning, 1996, Endocrine-Related Cancer, 3.41).To further study the transition state, two non-reactive ternary complexes, 17 beta-HSD1-EM519-N.4DP(+) and 17 beta-HSD1-EM553-NADP(+) were crystallized using combined methods of soaking and co-crystallization. Although they belong to the same C2 space group, they have different unit cells, with a = 155.59 Angstrom, b = 42.82 Angstrom, c = 121.15 Angstrom, beta = 128.5 degrees for 17 beta-HSD1-EM553-NADP(+), and a=124.01 Angstrom, b=45.16 Angstrom, c=61.40 Angstrom, beta=99.2 degrees for 17 beta-HSD1-EM553-NADP(+), respectively. Our preliminary results revealed that the inhibitors interact differently with the enzyme than do the natural substrates. (C) 1999 Elsevier Science Ltd. All rights reserved.
-
Synthesis of new derivatives of 21-imidazolyl-16-dehydropregnenolone as inhibitors of 5α-reductase 2 and with cytotoxic activity in cancer cells
Aylin Viviana Silva-Ortiz,Eugene Bratoeff,Teresa Ramírez-Apan,Yvonne Heuze,Juan Soriano,Isabel Moreno,Marisol Bravo,Lucero Bautista,Marisa Cabeza
DOI: https://doi.org/10.1016/j.bmc.2017.01.018
2017-03-01
Abstract:The aim of this study was to synthesize several 16-dehydropregnenolone derivatives containing an imidazole ring at C-21 and a different ester moiety at C-3 as inhibitors of 5α-reductase 1 and 2 isoenzymes. Their binding capacity to the androgen receptor (AR) was also studied. Additionally, we evaluated their pharmacological effect in a castrated hamster model and their cytotoxic activity on a panel of cancer cells (PC-3, MCF7, SK-LU-1). The results showed that only the derivatives with an alicyclic ester at C-3 showed 5α-R2 enzyme inhibition activity, the most potent of them being 21-(1H-imidazol-1-yl)-20-oxopregna-5,16-dien-3β-yl-cyclohexanecarboxylate with an IC50 of 29nM. This is important because prostatic benign hyperplasia is directly associated with the presence of 5α-R2. However, all the derivatives failed to inhibit 5α-R1 or bind to the AR. These alicyclic ester derivatives decreased the weight and size of androgen-dependent glands in the hamster, indicating they are very active in vivo and are not toxic. In addition, the 21-(1H-imidazol-1-yl)-20-oxopregna-5,16-dien-3β-yl-acetate derivative showed the highest cytotoxic activity on the three cancer cell lines studied. It is therefore important in the synthesis of steroidal compounds to consider the size of the ester moiety at C-3 of the steroid skeleton, which is key in obtaining biological activity, as observed in this experiment.